Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Nov 17;1(2):e2009010.
doi: 10.4084/MJHID.2009.010.

Immunotherapy for epstein-barr virus-related lymphomas

Alana A Kennedy-Nasser  1 , Catherine M Bollard, Helen E Heslop
Affiliations

Immunotherapy for epstein-barr virus-related lymphomas

Alana A Kennedy-Nasser et al. Mediterr J Hematol Infect Dis. .

Abstract

Latent EBV infection is associated with several malignancies, including EBV post-transplant lymphoproliferative disorders (LPD), Hodgkin and non-Hodgkin lymphomas, nasopharyngeal carcinoma and Burkitt lymphoma. The range of expression of latent EBV antigens varies in these tumors, which influences how susceptible the tumors are to immunotherapeutic approaches. Tumors expressing type III latency, such as in LPD, express the widest array of EBV antigens making them the most susceptible to immunotherapy. Treatment strategies for EBV-related tumors include restoring normal cellular immunity by adoptive immunotherapy with EBV-specific T cells and targeting the malignant B cells with monoclonal antibodies. We review the current immunotherapies and future studies aimed at targeting EBV antigen expression in these tumors.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Types of EBV Latency
See this image and copyright information in PMC

References

    1. Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343:481–492. - PubMed
    1. Khanna R, Moss D, Gandhi M. Technology insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies. Nat Clin Pract Oncol. 2005;2:138–149. - PubMed
    1. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004;4:757–768. - PubMed
    1. Ambinder RF. Epstein-barr virus and hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2007;2007:204–209. - PubMed
    1. Heslop HE. Biology and treatment of epstein-barr virus-associated non-hodgkin lymphomas. Hematology (Am Soc Hematol Educ Program) 2005:260–266. - PubMed

LinkOut - more resources